AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has accepted the supplemental biologics license application ...

Jefferies analyst Peter Welford maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of £114.00.

Owkin has partnered with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer. Takeaway Points Owkin has ...

AstraZeneca (NASDAQ:AZN) and partner Daiichi Sanyko (OTCPK:DSKYF)(OTCPK:DSNKY) said the FDA has accepted their application ...

Bank of America Securities analyst Sachin Jain has reiterated their bullish stance on AZN stock, giving a Buy rating on September 30. Sachin ...

(Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of ...

The solution will use Owkin's data network and artificial intelligence to prescreen for gBRCA mutations in breast cancer directly from digital pathology slides.

The Israeli-American unicorn company ImmunAI has signed a multi-year cooperation agreement with the pharmaceutical giant ...

AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...

AstraZeneca’s share price has fallen following unfavourable results for one of its new drugs, but others look good, and ...

In several short films directed by Reed Morano, the “What science can do” campaign features stories from a cancer patient and an asthma patient.

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and ...